Drugs / CAR.5/IL15-transduced CB-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05110742 | Apr 2024 → Dec 2027 expected | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR.5/IL15-transduced CB-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05110742 ↗ |
| Modality | Cell therapy | “CAR.5/IL15-transduced CB-NK cells” NCT05110742 ↗ |
| Route | Intravenous | “Given by IV” NCT05110742 ↗ |
| Target | CD5 | “CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells” NCT05110742 ↗ |